What does Senti Biosciences do?

Senti focuses on designing programmable genetic circuits for cell therapies and biologics, aiming to improve specificity and safety in therapeutic cells. Much of its work is early-stage and preclinical.

Is SNTI profitable or revenue-generating?

As a small, early-stage biotech company, Senti is primarily focused on R&D and is unlikely to be profitable. Revenue may come from partnerships or future product sales, but timelines are uncertain.

What are the main risks of investing in SNTI?

Key risks include clinical and technical failure, regulatory setbacks, funding dilution from future capital raises, low liquidity and high share-price volatility. Small-cap biotechs can move sharply on news.

How can I keep track of the company?

Watch regulatory filings, clinical updates, partnership announcements and quarterly results. Company press releases and official filings are primary sources; consider professional research for deeper analysis.

Is this stock suitable for me?

This is educational information, not personalised advice. SNTI is generally suited to investors comfortable with high-risk, long‑horizon biotech exposure. Consider your financial situation and, if unsure, consult a financial adviser.

Senti Biosciences (SNTI) Stock

Early stage biotech developing programmable cell therapies. Here's the price, business snapshot, and what's worth knowing about Senti Biosciences in October 2026.

Senti Biosciences (SNTI) is a synthetic biology company developing programmable cell therapies and biologics. Using a proprietary genetic-circuit platform, the company aims to design cells that respond selectively in the body, with potential applications in oncology and inflammatory disease. The business is early‑stage and largely preclinical; progress depends on R&D milestones, partnerships and future financing. With a market capitalisation of about $53.6m, Senti is a small-cap biotech and can be volatile — clinical setbacks, regulatory hurdles and funding needs may materially affect the share price. Investors should monitor pipeline updates, cash runway, partner deals and regulatory progress. This summary is for general educational purposes only and does not constitute personalised investment advice. Biotech investments carry high risk and it is sensible to consider diversification and whether this fits your risk tolerance before investing.

Sixth Month Growth Performance

$0.32

-0.69 (68.09%)past 6 months

≈

Stock Performance Snapshot

Buy

Analyst Rating

Analysts recommend buying Senti Biosciences stock, expecting it to rise significantly to $13.5.

Below Average

Financial Health

Senti Biosciences is struggling with low revenue and cash flow, indicating financial challenges.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

View more stocks by downloading the app for FREE

It only takes 60 seconds.

Why You’ll Want to Watch This Stock

📈

Early-stage biotech growth

Pipeline progress and clinical milestones can move the stock, though outcomes are uncertain and future capital raises may dilute shareholders.

⚡

Platform innovation focus

Programmable genetic circuits aim to improve therapeutic precision, but technological and regulatory hurdles mean success is not guaranteed.

🌍

Partnerships and funding

Collaborations and financing often drive development pace; watch cash runway and deal announcements as key signals of momentum.

Why invest with Nemo?

🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

Frequently asked questions

Senti Biosciences (SNTI) Stock

Early stage biotech developing programmable cell therapies. Here's the price, business snapshot, and what's worth knowing about Senti Biosciences in October 2026.